AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Okorieokorocha

Published November 9, 2026

What Did the Confirmatory Phase 3 MDMA -Assisted Therapy Trial Add?

Read the full story at Okorieokorocha

How was MAPP2 designed? The multisite study randomized 104 adults: 53 to MDMA -assisted therapy and 51 to placebo with the same manualized therapy.

Post on X

Share this story

Surfaced by this Google Alert

MDMA